Skip to main content
Two female scientists review test results

Delivery Platforms
Our Breakthrough Technology For
Hepatic and Nonhepatic Delivery

Our Proprietary Delivery Platforms

Ractigen Therapeutics values the importance of oligonucleotide delivery technologies. We have created our own in-house platforms enabling clinical development of oligonucleotide therapeutics. Our science represents an innovative jump in delivery technologies unlocking the door to tissues and organs historically cutoff from oligonucleotide therapeutics.

Simplified Manufacturing

An added benefit of all our delivery technologies is the simplicity in manufacturing. All conjugations and chemistries are compatible with classic oligonucleotide synthesis. The entire process is performed on-support using standard phosphoramidite chemistry eliminating the need of secondary manufacturing steps typical for nanoparticle formulations and many other conjugates.

Our SCAD System

Smart Chemistry-Aided Delivery (SCAD)

Ractigen boasts the creation of a breakthrough platform technology termed Smart Chemistry-Aided Delivery (SCAD) for delivery to the Central Nervous System (CNS).

By judicious use of chemical modifications and conjugation to an accessory oligonucleotide (ACO), our proprietary SCAD system endows self-delivering properties including broad tissue biodistribution and durable activity otherwise not previously possible with duplex oligonucleotides (e.g., siRNA and saRNA).

Our LiCO

Leveraging SDL Technology

SDL (Smart Diverse Linker) is a versatile linker utilizing innovative chemistry for conjugating one or more targeting moieties to an oligonucleotide.

Lipid-Conjugated Oligonucleotide (LiCO)

Using a novel lipid chemistry, LiCO revolutionizes oligonucleotide delivery by providing access to the heart, skeletal muscles, and beyond.

Our GLORY Platform

GaINAc-Oligonucleotide Liver Delivery (GLORY)

By leveraging our SDL technology, Ractigen has created the GLORY platform that compares favorably with industry benchmarks for liver delivery of duplex RNA.

How Can Our Delivery Platforms Help You?

We seek to explore the broad potential of our delivery platforms through research collaborations and licensing agreements in multiple therapeutic areas and applications.

For more information, please contact us.